Me1: A Promising Drug Target and Biomarker (G4199)

Target Name: ME1

NCBI ID: G4199

Content of Review Report on ME1 Target / Biomarker

ME1

Me1: A Promising Drug Target and Biomarker

ME1 (NADP-ME), or Nicotinamide adenine dinucleotide-mevalonate, is a drug target and a biomarker that is currently being studied for its potential therapeutic benefits in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

ME1 is a nucleotide derivative that is derived from adenine dinucleotide, which is a molecule that contains two nucleotides, adenine and guanine. ME1 has been shown to have a variety of biological activities and pharmacological effects, including the ability to inhibit the activity of the protein kinase PDK4 and the DNA-protein binding protein, HDACs.

One of the main reasons for the interest in ME1 is its potential as a drug target is its ability to intervene in the cell signaling pathways that are involved in cancer, neurodegenerative diseases, and cardiovascular disease. For example, ME1 has been shown to inhibit the activity of PDK4, which is a protein that is involved in cell signaling pathways that promote the growth and survival of cancer cells. This suggests that ME1 may have potential as a cancer therapeutic.

In addition to its potential as a cancer therapeutic, ME1 has also been shown to be involved in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles , which are thought to contribute to the symptoms of these diseases. ME1 has been shown to protect against neurofibrillary tangles and to stimulate the growth of new neurons in the brain, which may have potential as a neurodegenerative disease therapeutic.

Another potential application of ME1 is its use as a biomarker for the diagnosis and prognosis of cardiovascular disease. The cardiovascular system is a complex system that is responsible for delivering oxygen to the body's cells and is critical for maintaining the overall health and function of the body . ME1 has been shown to be involved in the regulation of the blood pressure and to have potential as a cardiovascular disease diagnostic and therapeutic.

In conclusion, ME1 is a drug target and biomarker that has the potential to improve the health and function of the body. Further research is needed to fully understand its potential applications and to develop safe and effective treatments for a variety of diseases.

Protein Name: Malic Enzyme 1

Functions: Catalyzes the oxidative decarboxylation of (S)-malate in the presence of NADP(+) and divalent metal ions, and decarboxylation of oxaloacetate

The "ME1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ME1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets